2020/11/27  
英文 English 
Taiwan seeking to acquire cheap and effective Oxford COVID Vaccine  (2020/11/20)

More good news on the race for a COVID vaccine. A vaccine candidate developed by the University of Oxford and pharmaceutical giant AstraZeneca has been found to offer a strong immune response in older adults and it could hit the market by year's end. It's production process is simpler than that of other COVID vaccine candidates, as reflected in its low price of $3 to $4 US dollars per dose. It's also easier to transport, as it can be stored in temperatures as high as 2 to 8 degrees Celsius. Taiwan's Central Epidemic Command Center says it's in talks to acquire the vaccine through the Covax vaccine alliance.

The coronavirus vaccine candidate developed by the University of Oxford and AstraZeneca is showing promising results. Phase II clinical trials have shown a strong immune response in older adults, offering almost 99% protection.

Lee Ping-ing
CECC expert advisory panel
Most of the people that develop severe COVID symptoms are over 65 years old. This is a group that especially needs protection. If the vaccine is effective - even if it is less effective than on younger adults - it's still worth administering.

Three vaccine candidates are expected to soon hit the market. One is the vaccine developed by Pfizer and BioNTech, which offers 95% protection. Each dose of the vaccine is reported to cost US$20. Moderna's vaccine offers 94.5% immunity and is priced at US$32 to US$37 per dose. Meanwhile, the vaccine developed by the University of Oxford is considerably cheaper, costing between US$3 to US$4 per dose.

Lee Ping-ing
CECC expert advisory panel
I think the different prices are something that depends on each vaccine developer's business strategy. Whether the vaccine is expensive or cheap doesn't mean it's better or worse.

The Oxford vaccine can be stored in temperatures as high as 2 to 8 degrees Celsius, making it easily shippable in addition to affordable. Taiwan's Central Epidemic Command Center says it inquired about acquiring the vaccine earlier this year.

Chuang Jen-hsiang
CECC spokesman
We used to call the vaccine developed by the University of Oxford the AZ vaccine. So regarding the AZ vaccine, we got in contact with them back in August and September. Now, we're communicating directly with the manufacturer through Covax. The process is quite smooth. As for whether we'll be able to purchase some vaccines is something we are proactively discussing at the moment.

The central government has been trying to secure vaccines to distribute in Taiwan. Meanwhile, local vaccine developers are working hard to enter Phase II clinical trials by year's end.
中文 Chinese  
牛津疫苗有強大免疫反應 我國已接洽

繼輝瑞BNT、莫德納疫苗後,英國牛津大學和阿斯特捷利康公司合作研發疫苗,也宣布在年長受試者產生強大免疫反應,有機會也在年底問世。由於它製程相對簡單,售價比輝瑞便宜近7倍,保存、運送也更方便。指揮中心週五證實,八九月時,就已經向藥廠爭取這款疫苗。

英國牛津大學和阿斯特捷利康公司研發出武肺疫苗,二期臨床試驗在年長受試者發現強大免疫反應,號稱保護力幾乎達99%。

[[疫情指揮中心專家小組諮詢委員 李秉穎]]
"武肺病毒的重症患者,絕大部分都是65歲以上的,這些族群需要特別保護,疫苗有效的話即使它是比年輕人,有效性低一點,但是也值得去打這些疫苗。"

目前全球已有三支疫苗走在最前面,包括輝瑞和BNT合作的疫苗,防護力有95%,預定售價20美元,莫德納疫苗防護力也有94.5%,售價將落在32到37美元,牛津大學這支疫苗,3到4美元最便宜。

[[疫情指揮中心專家小組諮詢委員 李秉穎]]
"市場價格的問題,我想是主要牽涉到疫苗廠的一個商業策略,什麼疫苗貴,什麼疫苗便宜,不一定代表說這個疫苗,是比較好或比較壞。"

尤其牛津大學疫苗只需要2到8度C環境就能保存,更方便運送,加上價格便宜,指揮中心證實已搶先洽詢。

[[疫情指揮中心發言人 莊人祥]]
"牛津大學這個我們以前叫做AZ啦,AZ相關的疫苗,我們也是大概在八九月的時候,就有開始接觸了,那目前也是一樣透過COVAX,跟廠商這邊直接聯繫。作業的部分也都相當良好,有關疫苗是不是可以購買的部分,我們正在積極洽談當中。"

中央多方接觸找疫苗,希望盡快取得授權,本土疫苗也力拼年底進入二期臨床試驗。


關於民視 常見問題 如何收看民視 意見信箱

© 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。